Novozymes Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Ester Baiget

Chief Executive Officer (CEO)

kr.29.1m

Compensación total

Porcentaje del salario del CEO	33.3%
Permanencia del CEO	4.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ester Baiget en comparación con los beneficios de Novozymes?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	kr.29m	kr.10m	kr.3b
Sep 30 2023	n/a	n/a	kr.3b
Jun 30 2023	n/a	n/a	kr.3b
Mar 31 2023	n/a	n/a	kr.4b
Dec 31 2022	kr.24m	kr.10m	kr.4b
Sep 30 2022	n/a	n/a	kr.3b
Jun 30 2022	n/a	n/a	kr.3b
Mar 31 2022	n/a	n/a	kr.3b
Dec 31 2021	kr.24m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.3b
Dec 31 2020	kr.24m	kr.7m	kr.3b

Compensación vs. Mercado: La compensación total de Ester($USD4.17M) está por debajo de la media de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Ester ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Ester Baiget (52 yo)

4.3yrs

Permanencia

kr.29,100,000

Compensación

Ms. Ester Baiget serves as Chief Executive Officer and President of Novozymes A/S since joining on February 1, 2020. She serves as Member of Supervisory Board at Akzo Nobel N.V. since 2022. She served as t...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ester Baiget	President & CEO	4.3yrs	kr.29.10m	sin datos
Rainer Lehmann	Executive VP & CFO	less than a year	kr.6.40m	sin datos
Anders Lund	Chief Operating Officer	less than a year	kr.7.70m	sin datos
Claus Fuglsang	Chief Scientific Officer	3.7yrs	sin datos	sin datos
Tobias Bjorklund	Head of Investor Relations	no data	sin datos	sin datos
Winnie Bugel	General Counsel of Legal	less than a year	sin datos	sin datos
Tue Micheelsen	Vice President of Global Sales & Marketing	no data	sin datos	sin datos
Morten Rasmussen	Executive Vice President of People & Stakeholder Relations	3.1yrs	sin datos	sin datos
Tina Fano	Executive Vice President of Planetary Health Biosolutions	8.3yrs	kr.7.60m	sin datos
Amy Byrick	Executive Vice President of Human Health Biosolutions	3.1yrs	sin datos	sin datos
Henrik Nielsen	Executive Vice President of Strategy & Integration	less than a year	sin datos	sin datos
Jacob Paulsen	Executive Vice President of Food & Beverage Biosolutions	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NVZM.F no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jesper Brandgaard	Vice Chair of the Board	less than a year	sin datos	sin datos
Cornelis de Jong	Independent Chairman	4.3yrs	kr.1.78m	0.0011% DKK 299.7k
Kim Stratton	Independent Vice Chair	7.3yrs	kr.1.29m	sin datos
Kasim Kutay	Director	7.3yrs	kr.803.00k	0.00023% DKK 63.8k
Heine Dalsgaard	Director	4.3yrs	kr.1.07m	0.00065% DKK 180.4k
Lise Kaae	Director	less than a year	sin datos	sin datos
Anders Knudsen	Employee Representative Director	11.3yrs	kr.535.00k	sin datos
Sharon James	Independent Director	4.3yrs	kr.1.07m	sin datos
Anne Breum	Employee Representative Director	3.2yrs	kr.535.00k	0.00010% DKK 27.8k
Preben Nielsen	Employee Representative Director	3.2yrs	kr.803.00k	0.000090% DKK 25.0k
Jens Obro	Employee Representative Director	3.2yrs	kr.535.00k	0.00012% DKK 33.3k
Morten Otto Sommer	Independent Director	2.2yrs	kr.1.03m	0.00022% DKK 61.1k

3.7yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de NVZM.F se considera experimentada (3.6 años de antigüedad promedio).

Novozymes Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Novozymes A/S Announces Board Appointments

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S Announces Executive Appointments, Effective April 2021

Novozymes A/S Announces Executive Changes

Recent updates

Novonesis Provides Sales Guidance for the Year 2024

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

Novozymes A/S Announces Change to the Executive Leadership Team

Novozymes A/S Provides Earnings Guidance for the Year 2023

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Novozymes A/S Provides Earnings Guidance for the Year 2022

Novozymes A/S to Report First Half, 2023 Results on Aug 09, 2023

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Novozymes A/S Provides Revenue Guidance for 2022

Novozymes A/S (CPSE:NZYM B) completed the acquisition of a 60% stake in Synergia Life Sciences Pvt. Ltd. for DKK 1 billion.

Novozymes A/S Provides Earnings Guidance for the Full Year 2021

Novozymes A/S Reaffirms Sales Guidance for the Year 2021

Univar Solutions and Novozymes® Partner to Bring Innovative, Sustainable Biotechnology Products to Customers in the United States and Canada

Novozymes Acquires Data Science Platform of Biota to Strengthen Microbiome R&D Capabilities in Probiotic Development

Novozymes A/S (CPSE:NZYM B) acquired the Microbiome R&D Team and Data Science Platform from Biota Technology, Inc.

Novozymes A/S Announces Executive Appointments, Effective April 2021

Fmc Corporation Collaborates with Novozymes A/S to Co-Develop Enzyme Solutions

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Microbiome Labs.

Novozymes A/S (CPSE:NZYM B) entered into an agreement to acquire Microbiome Labs for $250 million

Novozymes A/S to Report Fiscal Year 2020 Results on Jan 01, 2021

Novozymes A/S Announces Executive Changes

Novozymes A/S Announces Executive Changes

Firmenich and Novozymes Partner for Great-Tasting Yogurt with Unprecedented Sugar Reduction Performance

Novozymes A/S (CPSE:NZYM B) acquired Precisionbiotics Group Limited for €80 million.

Novozymes Omits to Provide Outlook for Second Half and Full Year of 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad